DPP-4(Dipeptidyl peptidase-4) inhibitor Sitagliptin Phosphate Hydrate study to the inhibition of extension atherosclerosis

DPP-4(Dipeptidyl peptidase-4) inhibitor Sitagliptin Phosphate Hydrate study to the inhibition of extension atherosclerosis - Study of DPP-4 inhibitor for preventing artheriosclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004881

Enrollment

Registered

2011-01-14

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 diabetes mellitus (borderline)

Interventions

intake of DPP-4 inhibitor not intake of DPP-4 inhibitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Is borderline type2 diabetes mellitus regardless of meal therapy and exercise training more than 1month (2010 Guideline of Diabetes mellitus society) and meet at least following requirement. 1.Diagnosis of borderline type2 diabetes mellitus (75g OGTT 2hours score and FBS score). 2.over the 20 years and under the 85 years. (man or women are not problem.) 3. for the first time, the outpatient who take no diabetic medecine or at least take only one another diabetic medicine(Insuline secretagogue, Biguanide, A-glucosidase inhibitor) more than 6 months.

Exclusion criteria

Exclusion criteria: 1.Has a history of allergy to Sitagliptin Phosphate Hydrate 2.Has a history of severe ketosis, diabetic coma and type1 diabetes mellitus 3.Has a history of severe renal insufficiency (hemodialysis or peritoneal dialysis patients) 4.Has a history of severe infection, perioperative term and severe wound 5.Has a overt systemic disease (liver cirrhosis, thyroid gland disease and nephrotic syndrome and so on) 6.Is not appropriate in the investigators' opinion

Design outcomes

Primary

Measure	Time frame
1.serum lipd marker, saccharometabolism marker (HbA1c, fasting blood sugar score, fasting insulin score, adiponectin) 2.Parameters of atherosclerosis (flow-mediated dialatation (FMD), Ankle-brachial index(ABI)/pulse wave velosity(PWV) score, the thickness of carotid artery inner membrane) 3.another points of atherosclerosis (the echo of cartid artery (PI value, RI value))	—

Secondary

Measure	Time frame
1.blod pressure, body weight, waist, BMI 2.liver function test(AST, ALT. g-GTP, LDH) 3.kidney function test(sCr, uCr, BUN, urine Alb)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026